Product details
Peptuno supplies Retatrutide (investigational development code LY3437943) as a sequence-verified analytical reference standard for tri-agonist incretin research. It is a 39-residue synthetic peptide that engages three receptors — GIP, GLP-1, and glucagon — and it is the glucagon arm that separates it from the dual-agonist entities, layering a direct hepatic-energy-expenditure mechanism on top of the incretin signalling; that third axis is the mechanistic rationale offered for the larger body-composition readouts in its published Phase 2 metabolic-research literature. As an investigational molecule it is not an approved finished drug anywhere, and the material here is characterized and labelled strictly as a research reagent.
Production volume for this peptide is far smaller than for Semaglutide or Tirzepatide, so the closely-eluting deletion-sequence profile of a low-throughput 39-mer SPPS run is the dominant analytical concern. Each lot is therefore released with RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer — with the tandem-MS sequence read recommended at first-time qualification, since intact mass alone cannot resolve a correct 39-mer from its deletion by-products. Bacterial endotoxin (LAL) and microbial limits are available on request for in vivo metabolic-model work. Fills run mg-scale for reproducible aliquoting; this is reference-grade research material, distinct from compounding-scale API supply.
Regulatory note: Investigational compound in clinical development; not approved as a finished drug in any jurisdiction. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
FAQ
- What is Retatrutide's reference identity, and why is formula/MW often shown as 'per COA'?
- Retatrutide CAS is 2381089-83-2. It is a 39-amino-acid synthetic peptide with C20 fatty-diacid lipidation. Because it is still investigational and salt/counter-ion form varies across sources, the precise molecular formula and average mass are best taken from the batch COA for the specific lot rather than a single catalog value; Peptuno confirms identity by ESI-MS against the theoretical mass for the supplied form and reproduces that value on the COA so it can be cited directly.
- How is Retatrutide pharmacologically different from Tirzepatide?
- Tirzepatide is a dual GIP / GLP-1 agonist; Retatrutide adds glucagon-receptor agonism for tri-mechanism activity. The glucagon arm contributes a hepatic-energy-expenditure component absent from the dual-agonist class, which in the published Phase 2 metabolic-research literature corresponds to larger body-composition effects than prior incretin agents at comparable exposures. Both are 39-amino-acid peptides with C20 fatty-diacid lipidation, but the receptor-binding determinants differ, which is why they are frequent comparators in incretin-pharmacology studies.
- What identity testing should a lab request when qualifying Retatrutide from a new source?
- Request the tandem-MS (LC-MS/MS) sequence-verification result on the first lot in addition to RP-HPLC purity and ESI-MS intact mass. For a low-volume 39-mer, deletion and aspartimide by-products co-elute closely on RP-HPLC and are not separable by intact mass alone; the b/y-ion ladder from LC-MS/MS is the test that demonstrates the supplied sequence matches the labelled sequence. For in vivo metabolic-model work, also request bacterial endotoxin (LAL) on the specific lot.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.